Sitazit (Sitagliptin Hydrochloride)

Sitazit (Sitagliptin Hydrochloride) is an oral antidiabetic medication and DPP-4 inhibitor designed to help adults manage type 2 diabetes mellitus by improving blood glucose control. This prescription tablet works by blocking the dipeptidyl peptidase-4 enzyme, which protects incretin hormones and stimulates insulin release from the pancreas when blood sugar levels are elevated. Simultaneously, it reduces glucagon secretion and decreases glucose production by the liver, creating a dual mechanism that naturally regulates blood sugar without triggering dangerous drops in glucose levels.

Sitazit is particularly valued for its glucose-dependent action, which significantly lowers the risk of hypoglycemia compared to other diabetes medications, especially when used without sulfonylureas or insulin. The medication is weight-neutral and convenient—requiring only a single daily dose—making it an ideal choice for patients seeking straightforward diabetes management. It is commonly prescribed as monotherapy for patients who cannot tolerate metformin, or combined with metformin, SGLT2 inhibitors, or insulin to achieve enhanced glycemic control and improved HbA1c levels.

This medication is suitable for adult patients only and must be taken at the exact dose prescribed by your healthcare provider. Sitazit has earned recognition in diabetes management guidelines as a reliable add-on therapy for patients requiring better blood sugar regulation, offering a well-tolerated option that fits seamlessly into comprehensive diabetes care plans.